2016 Press Releases

Home»2016 Press Releases
6 09, 2016

Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th

2017-02-07T17:25:55+00:00

Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th PALO ALTO, Calif., September 6, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will [...]

Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th2017-02-07T17:25:55+00:00
1 09, 2016

Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016

2017-02-07T17:27:24+00:00

Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016 PALO ALTO, Calif., September 1, 2016 — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco. Eiger BioPharmaceuticals management is scheduled [...]

Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 20162017-02-07T17:27:24+00:00
18 08, 2016

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

2017-02-07T17:29:00+00:00

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PALO ALTO, Calif., August 18, 2016 /PR Newswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,250,000 shares of its [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock2017-02-07T17:29:00+00:00
18 08, 2016

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2017-02-07T17:30:21+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., August 17, 2016 /PR Newswire/ – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock2017-02-07T17:30:21+00:00
11 08, 2016

Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results

2017-02-07T17:31:53+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results - Four Product Candidates in Four Orphan Indications Advancing Toward Near-Term Milestones PALO ALTO, Calif., August 10, 2016 /PR Newswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the [...]

Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results2017-02-07T17:31:53+00:00
28 07, 2016

Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation

2017-02-07T17:33:30+00:00

Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation - Raising Awareness of Hepatitis Delta Virus Co-Infection PALO ALTO, Calif., July 28, 2016 / PRNewswire / — In support of World Hepatitis Day 2016, Eiger BioPharmaceuticals, Inc., a leader in the development of therapeutics for hepatitis delta infection, announced today that it is partnering with the [...]

Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation2017-02-07T17:33:30+00:00
25 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema

2017-02-07T17:36:18+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema Novel first-in-class inhibitor of LTB4 production targeting disease modification PALO ALTO, Calif., July 25, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema2017-02-07T17:36:18+00:00
25 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema

2017-02-07T16:22:56+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema Novel first-in-class inhibitor of LTB4 production targeting disease modification PALO ALTO, Calif., July 25, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema2017-02-07T16:22:56+00:00
20 07, 2016

Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH)

2017-02-07T17:38:33+00:00

Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH) PALO ALTO, Calif., July 20, 2016 / PRNewswire / — Eiger BioPharmaceuticals, Inc. today announced the completion of dosing of LOWR HDV – 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 3) at the National Institutes of [...]

Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH)2017-02-07T17:38:33+00:00
18 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

2017-02-07T17:40:25+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension Novel first-in-class inhibitor of LTB4 targeting disease modification PALO ALTO, Calif., July 18, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension2017-02-07T17:40:25+00:00